Yonkenafil_product_DataBase

Bioactivity	Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease[1].
In Vivo	Yonkenafil (4-32 mg/kg, i.v. daily for 7 days) 能够改善中风后的行为结果并减少脑梗塞体积，抑制神经元凋亡，并通过调节 BDNF/TrkB 和 NGF/TrkA 的表达显着增强缺血脑中的突触功能[1]。 Animal Model:
Name	Yonkenafil
CAS	804518-63-6
Formula	C24H33N5O4S
Molar Mass	487.61
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77.

PeptideDB